Furthermore, atypical AD patients show greater change over time in tau accumulation measured on PET compared to amnestic AD (Sintini et al., 2020), and, hence, it would be more feasible to assess longitudinal tau outcome measures in treatment trials in these patients. Here, MAPT is linked to Alzheimer disease.